TIL NASDAQ
Instil Bio, Inc.
1W: +0.9%
1M: -3.5%
3M: -11.3%
YTD: -27.9%
1Y: -50.6%
3Y: -33.8%
5Y: -97.7%
$8.18
+0.06 (+0.74%)
Weekly Expected Move ±4.0%
$7
$8
$8
$8
$9
Overview
News
Chart
Smart Money
Financials
Income Statement
Cash Flow
Balance Sheet
Earnings
Dividends
Analysis
Technicals
Weather
Peers
ESG
Institutions
ETF Exposure
Dark Pool
Short Interest
Supply Chain
Smart Money Score
Watch
25
Insider—
Congress—
ETF Holdings—
Key Statistics
Market Cap$55.5M
52W Range5.67-42.79
Volume17,822
Avg Volume29,401
Beta1.95
Dividend—
Analyst Ratings
Company Info
CEOBronson Crouch
Employees14
SectorHealthcare
IndustryBiotechnology
IPO Date2021-03-19
Websiteinstilbio.com
3963 Maple Avenue
Dallas, TX 75219
US
Dallas, TX 75219
US
972 499 3350
About Instil Bio, Inc.
Instil Bio, Inc., a clinical-stage biopharmaceutical company, develops therapies for the treatment of patients with cancer. The company develops cell therapy of autologous tumor infiltrating lymphocyte (TIL). Its TIL product candidates in pipeline include ITIL-168 for indications, such as melanoma, cutaneous squamous cell carcinoma, non-small cell lung cancer, head and neck squamous cell carcinoma, and cervical cancer; and ITIL-306 to recognize folate receptor alpha (FOLR1) with indications, including gynecological, non-small cell lung cancer, renal caner, and others. The company was incorporated in 2018 and is headquartered in Dallas, Texas.
Latest News
Instil Bio Reports First Quarter 2026 Financial Results and Provides Corporate Update
Instil Bio Reports First Quarter 2026 Financial Results and Provides Corporate Update
Instil Bio, Inc. Investigated by the Portnoy Law Firm
Earnings Scheduled For March 27, 2026
Instil Bio Non-GAAP EPS of -$0.97 beats by $2.81
Recent Insider Trades
| Name | Type | Shares | Price | Date |
|---|---|---|---|---|
| Laumas Sandeep | M-Exempt | 13,000 | $12.68 | 2025-09-10 |
| Laumas Sandeep | M-Exempt | 13,000 | $12.68 | 2025-09-10 |
| Laumas Sandeep | M-Exempt | 17,000 | $11.60 | 2025-09-10 |
| Laumas Sandeep | M-Exempt | 17,000 | $11.60 | 2025-09-10 |
| Laumas Sandeep | S-Sale | 17,539 | $23.04 | 2025-09-10 |